Takeda Pharmaceutical Co. Ltd.

As of June 30, 2026, Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR carries a market capitalization of 261.47B, placing it among publicly traded companies globally. Its enterprise value stands at 401.80B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR has 3.19B shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.11, and the price-to-book ratio stands at 1.09.

As of June 30, 2026, Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR trades at an EV/EBITDA multiple of 18.76 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.74 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 547.81 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 401.80B versus a market cap of 261.47B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR maintains a current ratio of 1.14, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 65.35, indicating elevated leverage, while an interest coverage ratio of 6.43 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR posted a negative return on equity (ROE) of -2.27, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.10, reflecting losses generated across the asset base. The company generates approximately 3.11M in revenue per employee across its workforce of 47,242.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.19 indicates how many times Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR recorded 1.05B in income tax expense. The company reported a pretax loss of -4.14B and -5.20B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 19, 2026, Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR's stock has gained approximately 31.06% over the past 52 weeks. The 50-day moving average sits at 89.29, while the 200-day moving average is 81.94.

Over the twelve months ended June 30, 2026, Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR generated 146.86B in revenue and converted that into -5.20B in net income, yielding earnings per share of -2.59. EBITDA reached 21.41B, while operating income came in at 15.30B.

As of June 30, 2026, Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR holds 16.78B in cash and equivalents against 157.07B in total debt, resulting in a net debt position of 142.41B. Total book value stands at 240.31B, with working capital of 12.26B providing operational flexibility.

Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR produced 26.27B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -10.80B in capital expenditures, free cash flow totaled 15.47B - equivalent to 7.80 per share.

Over the twelve months ended June 30, 2026, Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR posted a gross margin of 65.50, reflecting its pricing power and cost economics. The operating margin of 10.42 and net profit margin of -3.54 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR paid dividends of 2.67 per share. The dividend payout ratio of -102.30 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 9.44, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.43, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR shareholders.

As of June 30, 2026, Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR has an Altman Z-Score of 1.80, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.